Company intelligence / Profile preview

Genuone Sciences

Dongtan, Gyeonggi-do, South Koreagenewinbiotech.com ↗

Ownership: Private
Development stage: Commercial

Overview

Genuone Sciences is South Korea’s leading pharmaceutical CDMO with expertise in synthetic drugs and biologics. It offers comprehensive drug development, clinical trial support, manufacturing, and consulting services to major Korean pharma companies. The company exports over 250 products to 20 countries. It was established after acquiring Kolmar Korea’s pharmaceutical division in 2020 by IMM Private Equity and was acquired by Macquarie Asset Management in July 2024. Revenue reached approximately $393 million USD in 2023 with double-digit annual growth.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeBiologic
Industry: Contract Manufacturing Organization

Partnerships

Hanmi PharmaceuticalYuhan CorporationChong Kun DangLG Chem/LG Life Sciences

Beyond the preview

Go deeper on Genuone Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genuone Sciences.

Explore the full profile